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Abstract 
Objectives. Recent genome-wide association and functional studies have shown that the 
ABCG2 gene encodes for a urate transporter, and a common causal ABCG2 variant, 
rs2231142, leads to elevated uric acid levels and prevalent gout among whites and blacks. 
We examined whether this finding is observed in a Japanese population, since Asians have 
a high reported prevalence of the T risk allele. 
Methods. A total of 3,923 Japanese from the Circulatory Risk in Communities Study aged 
40-90 were genotyped for rs2231142. Associations of the rs2231142 variant with serum 
uric acid levels and prevalence of gout and hyperuricemia were examined.  
Results. The frequency of the T risk allele was 31% in this Japanese sample. Multivariable 
adjusted mean uric acid levels were 7-9μmol/L higher for TG and TT than GG carriers 
(p-additive=0.0006). The multivariable adjusted odds ratio of prevalent gout was 1.37(95% 
confidence interval: 0.68-2.76) for TG and 4.37(1.98-9.62) for TT compared with the GG 
carriers (p-additive=0.001). When evaluating the combined outcome of hyperuricemia and 
gout, the respective odds ratios were 1.40(1.04-1.87) for TG and 1.88(1.23-2.89) for TT 
carriers. The population attributable risk was 29% for gout and 19% for gout and/or 
hyperuricemia. 
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Conclusions. The association of the causal ABCG2 rs2231142 variant with uric acid levels 
and gout was confirmed in a sample of Japanese ancestry. Our study underscores the 
importance of this common causal variant in a population with a high risk allele frequency, 
especially as more Japanese adopt a Western lifestyle with a concomitant increase in mean 
serum uric acid levels. (250 words / 250 limits) 
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Introduction. 
Hyperuricemia is a key risk factor for gout and has been described as associated with 
cardiovascular risk factors and diseases such as hypertension, diabetes, metabolic syndrome, 
stroke and coronary heart disease [1]. Recently, Dehghan and colleagues conducted 
population-based genome-wide association studies and identified three genetic loci 
associated with increased serum uric acid concentration and prevalence of gout [2]. The 
most significant association at one of the loci was observed for a missense single nucleotide 
polymorphism (SNP), rs2231142 in the ABCG2 gene. Each copy of the T allele at 
rs2231142 was associated with gout in both white [odds ratio (95% confidence interval) 
=1.74 (1.51-1.99)] and black [1.71 (1.06-2.77)] study participants. In a subsequent 
functional study it was shown that ABCG2 is a urate transporter that mediates urate 
excretion in the kidney, and that the rs2231142 T allele encodes for a reduced-function 
mutation leading to reduced ability to excrete uric acid [3]. Interestingly, the risk allele is 
three times more frequent in the Japanese compared to the European-ancestry HapMap 
samples, but so far, the association of this locus with serum uric acid or prevalent gout has 
rarely examined in other races/ethnicities than whites and blacks. We therefore examined 
whether this association replicates in Japan, where prevalence of gout has rapidly increased 
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since the 1960s [4].  
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Methods. 
Ethics statement 
This study was approved by the Institutional Review Board of the University of Tsukuba. 
All participants whose data were analyzed in this study provided written informed consent 
for the collection of samples and subsequent analysis. 
 
Study population and measurement of exposure and outcomes  
The Circulatory Risk in Communities Study (CIRCS) is an ongoing dynamic community 
cohort study involving 5 communities in Japan. The rs2231142 variant in ABCG2 (Q141K) 
was genotyped in participants in community surveys in 2001 in Kyowa and in 2003 in 
Ikawa, as a part of the CIRCS. A total of 4,418 participants, 40 years or over, in these 
Japanese farming communities provided written informed consent for DNA analysis 
(consent rate =98%). The genotype was determined by the Intercalator mediated 
Fluorescence Resonance Energy Transfer probe method using Taq DNA polymerase (rTaq; 
Toyobo, Osaka, Japan) at the Tsuruga Laboratory of Toyobo Gene Analysis Co., Ltd (Osaka, 
Japan). Detailed methods for genotyping were described elsewhere [5]. The designed probe 
was 5'-AGAGAAAACTTACAGTTCTCAGCAG-3' with Texas Red-end, specific to G 
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allele. Serum uric acid and other health information were also collected [6]. Uric acid was 
measured by the uricase/peroxidase methods at the Osaka Medical Center for Health 
Science and Promotion (Osaka, Japan). History/treatment of gout and treatment of 
hyperuricemia were ascertained face-to-face by trained interviewers. Gout was defined if 
participants answered that they had experienced gout; had been diagnosed gout by 
physicians; or were under treatment for gout. Hyperuricemia was defined if they had a uric 
acid concentration of ≥415.9 μmol/L (7.0 mg/dL) based on blood testing; or answered that 
they were under treatment for hyperuricemia at interview. If they had had a uric acid 
concentration of ≥415.9 μmol/L, based on records from previous annual checkups, the 
interview confirmed whether or not the participants were now under treatment for 
hyperuricemia. We excluded persons with unsuccessful genotyping (n=1), missing DNA 
(n=70), and missing uric acid data (n=424). Ultimately, 3,923 participants were included in 
this study.  
 
Statistical analyses 
We used analysis of covariance for calculation of multivariable adjusted mean values of 
serum uric acid across genotypes, and multivariable adjusted logistic regression models for 
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calculation of odds ratios and 95% confidence intervals. We evaluated an additive genetic 
model (ie, genotypes were coded as 0 for GG, 1 for TG and 2 for TT genotypes) and also 
compared the TG and TT genotypes separately to the reference genotype GG; the 
Hosmer-Lemeshow test showed that the logistic regression models fit the data well for 
these analyses. To test for significance, we assumed an additive genetic model analogous to 
previously reported analyses [2]. We did not find a significant difference in the variance in 
uric acid concentration across the genotype groups using the Levene’s test (p=0.35). 
Although the distribution of uric acid concentration was not statistically normal 
(Kolmogorov-Smirnov p<0.01), we did not log-transform the values to permit 
comparability with the discovery report [2]. The distribution was virtually quasi-normal, 
and the log-transformation did not improve the normality. Covariates were selected to 
match covariates used in the discovery report [2], ie, age, sex, BMI (kg/m2), alcohol 
consumption (g/day), hypertension treatment and community. Population attributable risk 
fraction (%), which represents the percentage of gout that might be due to rs2231142, was 
calculated as [(PTG)(PRTG-1)+(PTT)(PRTT-1)] / [1+(PTG)(PRTG-1)+(PTT)(PRTT-1)] * 100, 
where PTG or PTT corresponds to the proportion of individuals exposed to TG or TT 
genotype among those without gout, and PRTG or PRTT is the respective unadjusted 
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prevalence ratio of gout/hyperuricemia. We used SAS version 9.1.3 Service Pack 4 (SAS 
Institute Inc., Cary, NC) for analyses. All probability values for statistical tests were 
two-tailed, and p<0.05 was regarded as statistically significant. 
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Results.   
The genotype distribution conformed to Hardy-Weinberg equilibrium (p≥0.54). The 
frequency of the risk allele (T) was 31% in this Japanese sample, much higher than that 
reported for whites (11-12%) and blacks (3%) by Dehghan et al. [2] (Table 1). Conversely, 
mean uric acid concentration was much lower in Japanese (282.1μmol/L) than reported for 
whites (315.2-350.9μmol/L) and blacks (374.7μmol/L). Age, body mass index (BMI), 
alcohol drinking and antihypertensive medication use did not differ substantially across the 
three genotype categories (Table 2).  
As shown in Table 3, mean uric acid concentration was 7-9μmol/L higher for TG 
and TT than GG carriers after adjustment for age, sex, community, BMI, alcohol 
consumption, and antihypertensive treatment (p-additive = 0.0006). While this association 
was linear in women, uric acid levels were lower among TT than TG carriers in men. The 
R2 for uric acid concentration was 0.279 in this multivariate model without ABCG2 and 
0.281 with ABCG2 genotype. 
Compared with the GG genotype, the multivariable adjusted odds ratio of gout was 
1.37 (95% confidence interval: 0.68-2.76) for TG and 4.37 (1.98-9.62) for TT carriers 
[p-additive =0.001, odds ratio =2.03 (1.33-3.12) per T allele] (Table 3). When we combined 
 12 
hyperuricemia (defined as hyperuricemia treatment and/or uric acid ≥415.9μmol/L) with 
gout as one outcome, the respective odds ratios were 1.40 (1.04-1.87) for TG and 1.88 
(1.23-2.89) for TT carriers [p-additive =0.002, odds ratio =1.38 (1.13-1.68) per T allele]. Of 
note, the recessive genetic model provided a better fit than the additive model for gout as 
indicated by a lower Akaike’s Information Criterion (p-recessive=0.0002).  
The population attributable fraction for rs2231142 was 29% for gout and 19% for 
gout and/or hyperuricemia.  
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Discussion   
Our study confirms the results by Dehghan et al. [2], a subsequent meta-analysis of 
European ancestry subjects [7], and some other case-control studies including those from 
Japan [8] and China [9], reporting an association of rs2231142 with serum uric acid levels 
and gout. In addition, it is the first study of rs2231142 in a community-based setting of 
Asian ancestry, a Japanese sample. Our finding is consistent with the recently established 
causality of the rs2231142 variant [3,8].  
Although the prevalence of the risk allele was higher among Japanese 
(31%) than whites (11-12%) and blacks (3%), serum uric acid levels and gout prevalence 
were much lower in this Japanese sample. Traditionally, gout was rarely observed among 
Japanese before the 1960’s. Since then, the prevalence of gout has rapidly increased [4], 
presumably because of rapid changes in lifestyle after World War II. This phenomenon is 
commonly observed with complex diseases, where adverse environmental exposures are 
thought to act on genetically susceptible individuals. Our findings may suggest a potential 
gene-environment interaction in relation to gout/uric acid resulting in an increased 
incidence of gout. That is, some factors that are part of a traditional Japanese lifestyle may 
protect from gout despite the high prevalence of the risk allele among 
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Japanese. This hypothesis is in line with the fact that US Asians have almost three times 
the prevalence of diagnosed gout than US whites [10], since US Asians might be exposed to 
both a high prevalence of the risk allele and US lifestyle. 
A limitation of this study is that we used the information of gout ascertained by a 
face-to-face interview. To our knowledge, no study has reported sensitivity, specificity or 
positive predictive value for interview in the diagnosis of gout based on a golden standard 
of clinical diagnosis. Another limitation is the moderate statistical power (approximately 
50-60%); since we found a positive association, this would not have affected the results 
materially. Third, the usage of the odds ratio might not be appropriate as an approximate of 
relative risk in cross-sectional study, because gout and hyperuricemia are not scarce in 
general Japanese population, although rarer than in the United States or Europe (Table 1). 
However, when we used an unadjusted prevalence ratio instead, the results did not change 
materially. Finally, we found in men that the uric acid level was lower among TT than TG 
carriers; this was due probably to small sample size in the TT stratum (n=158).   
A recent functional and association study of Japanese [8] has identified another 
causal SNP of ABCG2, Q126X, with less frequency of minor allele (1.8% among control), 
but stronger effect on gout/hyperuricemia than presently-analyzed ABCG2 (Q141K). A 
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combination of these two SNP may better predict gout/hyperuricemia in Japanese, which 
needs to be replicated in community-based samples. 
In conclusion, the T allele at rs2231142 in ABCG2 was associated with higher 
serum uric acid levels and gout prevalence among Japanese, consistent with the previous 
results from whites and blacks. The high frequency of this established causal variant among 
Japanese may have important implications for gout prevalence as more Japanese adopt a 
Western lifestyle. 
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Key Messages 
A newly identified common causal ABCG2 variant, rs2231142, has been reported to lead to 
elevated uric acid levels and prevalent gout among whites and blacks. We examined 
whether this finding is observed in a Japanese population who had a high prevalence of the 
risk allele. 
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Appendix 
CIRCS Investigators  
The Circulatory Risk in Communities Study (CIRCS) is a collaborative study managed by 
the Osaka Medical Center for Health Science and Promotion, University of Tsukuba, Osaka 
University and Ehime University. The CIRCS investigators who contributed to this study 
are as follows: Kazumasa Yamagishi, Mitsumasa Umesawa, Kyoko Kirii, Choy-Lye Chei, 
Kimiko Yokota, and Minako Tabata, University of Tsukuba, Tsukuba; Hiroyasu Iso, Tetsuya 
Ohira, Hironori Imano, Renzhe Cui, and Satoyo Ikehara, Osaka University, Suita; 
Masamitsu Konishi, Yoshinori Ishikawa, Masakazu Nakamura MD, Akihiko Kitamura, 
Masahiko Kiyama, Takeo Okada, Kenji Maeda, Masatoshi Ido, Masakazu Nakamura PhD, 
Takashi Shimamoto, Minoru Iida and Yoshio Komachi, Osaka Medical Center for Health 
Science and Promotion, Osaka; Shinichi Sato, Chiba Prefectural Institute of Public Health, 
Chiba; Takeshi Tanigawa, Isao Saito, Katsutoshi Okada, and Susumu Sakurai, Ehime 
University, Toon; Masayuki Yao, Ranryoen Hospital, Ibaraki; Ai Ikeda and Hiroyuki Noda, 
Harvard School of Public Health, Boston, MA. 
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Table 1. Comparison of the association between rs2231142 polymorphism and prevalent 
gout in community-based studies 
Study race/ethnicity sample size MAF UA (μmol/L) gout (%) aOR* (95%CI) 
Framingham  White 7,699  0.11 315.2  2.7  1.97 (1.49-2.59) 
Rotterdam White 4,148  0.12 321.2  3.3  1.71 (1.30-2.25) 
ARIC White 11,024  0.11 350.9  5.4  1.68 (1.38-2.04) 
(White pooled) White 22,871  - - - 1.74 (1.51-1.99) 
       
ARIC Black 3,843  0.03 374.7  8.8  1.71 (1.06-2.77) 
CIRCS Japanese 3,923  0.31 282.1  1.0  2.03 (1.33-3.12) 
       
MAF: minor allele frequency (ie, T allele frequency); UA: uric acid; aOR: additive odds ratio; CI: confidence interval; 
ARIC: Atherosclerosis Risk in Communities; CIRCS: Circulatory Risk in Communities Study. 
* aOR is the odds ratio for gout per copy increment of the T allele, adjusting for age, sex, body mass index, alcohol 
consumption, hypertension treatment, cohort status in Framingham, cohort and study center in ARIC and CIRCS. 
Data other than CIRCS were derived from Dehgan et al. [2]    
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Table 2. Characteristics of study participants according to rs2231142 genotype, 3,923 
Japanese men and women aged 40-90. 
  rs2231142 
  GG TG TT 
Men    
Participants (%) 706 (46) 670 (44) 158 (10) 
Age, yrs 63.2 (10.3) 63.0 (10.5) 64.1 (9.2) 
Body mass index, kg/m2 23.4 (2.9) 23.7 (3.0) 23.7 (3.2) 
Current drinker 495 (70.2) 490 (73.2) 107 (67.7) 
Alcohol drinking (g/d)* 29.6 (16.1, 46.0) 29.6 (18.4, 46.0) 29.6 (18.7, 46.0) 
Antihypertensive medication 212 (30.0) 186 (27.8) 53 (33.5) 
Diabetes† 70 (9.9) 62 (9.3) 16 (10.1) 
Uric acid, μmol/L 320.6 (71.2) 334.3 (76.6) 323.7 (77.8) 
Gout‡ 11 (1.6) 18 (2.7) 8 (5.1) 
Gout and/or hyperuricemia§ 78 (11) 107 (16) 26 (16.5) 
    
Women    
Participants (%) 1155 (48) 1003 (42) 231 (10) 
Age, yrs 61.1 (10.7) 61.4 (10.3) 62.8 (10.0) 
Body mass index, kg/m2 23.7 (3.4) 23.9 (3.5) 23.9 (3.1) 
Current drinker 127 (11.0) 112 (11.2) 29 (12.6) 
Alcohol drinking (g/d)* 6.6 (3.3-11.5) 6.6 (3.9-11.5) 4.9 (3.0-9.9) 
Antihypertensive medication 322 (27.9) 281 (28.0) 72 (31.2) 
Diabetes† 57 (4.9) 55 (5.5) 12 (5.2) 
Uric acid, μmol/L 250.1 (62.7) 254.8 (59.3) 263.7 (65.9) 
Gout‡ 4 (0.3) 0 (0.0) 4 (1.7) 
Gout and/or hyperuricemia§ 16 (1.4) 10 (1.0) 9 (3.9) 
Data are mean (SD) or n (percentage) unless indicated otherwise.   
*Median (1st and 3rd quartile) values among drinkers presented.  
†Diabetes was defined as fasting blood glucose ≥7.0mmol/L (126mg/dL) or non -fasting 
blood glucose ≥11.1mmol/L (200mg/dL), and/or treatment of diabetes.  
‡Gout was defined as a history of symptoms and/or past or present treatment of gout. 
§ Hyperuricemia was defined as uric acid of ≥415.9 μmol/L (7.0 mg/dL) , and/or treatment 
of hyperuricemia. 
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Table 3. Mean serum uric acid concentration (standard error), prevalence of gout and 
hyperuricemia according to ABCG2 rs2231142 genotype, 3,923 Japanese men and women aged 
40-90. 
 rs2231142  
  GG TG TT 
p for 
additive 
model† 
Uric acid concentration (μmol/L)     
Total, n 1,861  1,673  389   
  Age, sex and community-adjusted 277.6 (1.6) 286.0 (1.6) 287.1 (3.4) 0.0002 
  Multivariable adjusted* 278.2 (1.5) 285.5 (1.6) 286.8 (3.3) 0.0006 
Men, n 706  670  158   
  Age and community-adjusted 320.6 (2.8) 334.1 (2.9) 324.4 (5.9) 0.04 
  Multivariable adjusted* 321.2 (2.7) 333.7 (2.8) 324.0 (5.7) 0.05 
Women, n 1,155  1,003  231   
  Age and community-adjusted 250.1 (1.8) 254.9 (1.9) 263.2 (4.0) 0.002 
  Multivariable adjusted* 250.6 (1.7) 254.4 (1.9) 262.9 (3.9) 0.004 
     
Gout‡, n (%) 15 (1%) 18 (1%) 12 (3%)  
  Age, sex and community-adjusted OR 
  (95% confidence interval) 
1.0 1.34 
(0.67-2.68) 
4.18 
(1.92-9.10) 
0.002 
   Multivariable-adjusted OR* 
  (95% confidence interval) 
1.0 1.37 
(0.68-2.76) 
4.37 
(1.98-9.62) 
0.001 
     
Gout‡ and/or Hyperuricemia§, n (%) 94 (5%) 117 (7%) 35 (9%)  
  Age, sex and community-adjusted OR 
  (95% confidence interval) 
1.0 1.40 
(1.05-1.87) 
1.90 
(1.25-2.90) 
0.001 
   Multivariable-adjusted OR* 
  (95% confidence interval) 
1.0 1.40 
(1.04-1.87) 
1.88 
(1.23-2.89) 
0.002 
* Further adjusted for body mass index (kg/m2), daily alcohol consumption (g/day) and 
antihypertensive medication use. 
† Assigning 0 for GG, 1 for TG, and 2 for TT genotypes. 
‡Gout was defined as a history of symptoms and/or past or present treatment of gout.  
§ Hyperuricemia was defined as uric acid of ≥415.9 μmol/L (7.0 mg/dL), and/or treatment of 
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hyperuricemia. 
Persons missing covariates were eliminated from the multivariable adjusted analyses (n=9 
excluded). 
 
 
